Israeli medical diagnostic technology developer Micromedic Technologies Ltd., has announced positive intermediary results in its trial of CellDetect, a technology for detecting cervical cancer. The results show a 94 percent success rate. In light of these results, Micromedic’s share price rose 10.48 percent.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
UK Adopts Israeli Counter-Drone Technology
April 25, 2024
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments